Obsolescence of Products Handled and Changes in Treatment Methods
First written in FY2019. 10 of 18 entries say "Materialised", first in FY2022-Q3. Latest entry: FY2026.
Japan Lifeline moved to the "Worse" side of this theme in 2021, 5 years before the typical company in this theme (2026).
The whole theme swung hardest in 2026: 28 of 57 companies on the "Worse" side.
8 other companies' latest entry also says "Materialised".
- FY2026MaterialisedAnnual report
「As pulsed-field ablation (PFA), a new treatment for atrial fibrillation, rapidly gains acceptance, certain EP catheters, including esophageal temperature-monitoring catheters, performed poorly.」
The adoption of the new PFA technology was reflected in sluggish sales of some EP catheters used for conventional treatments. - FY2026-H1MaterialisedAnnual report
「Meanwhile, as PFA, a new treatment for atrial fibrillation being promoted by other companies, gained traction, sales of some EP catheters, including esophageal temperature-monitoring catheters, remained sluggish.」
The adoption of PFA, a new treatment method, was reflected in sluggish sales of some EP catheters, including esophageal temperature-monitoring catheters. - FY2025WorsenedAnnual report
「In particular, four one-of-a-kind or core products, namely the S-ICD (subcutaneous implantable cardioverter-defibrillator), intracardiac defibrillation catheters, Frozen Elephant Trunk, and femoral venous hemostasis devices, accounted for approximately 50% of sales in the fiscal year ended March 2025. We recognize that the risk, if it materializes, could have a certain impact.」
The potential impact of product obsolescence due to new competitors entering the market and changes in treatment methods was quantified, with the four main products accounting for approximately 50% of sales for the period. - FY2025-H1RestatedAnnual report
「No new business or other risks arose during the current interim consolidated accounting period. In addition, there were no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company disclosed that there had been no material changes in the risk of declining market share due to product obsolescence and changes in treatment methods. - FY2024-Q3MaterialisedAnnual report
「Our open stent graft FROZENIX was slightly affected by a new competitor entering the market in the third quarter, but sales remained firm, supported by the development of new customers and market expansion.」
Although FROZENIX was in fact affected by a new competitor entering the market, sales remained firm due to the development of new customers and market expansion. - FY2023MaterialisedAnnual report
「Although the high-frequency atrial septal puncture needle RF Needle had been sold as a unique product for many years since sales began in 2013, a competing product was launched in the previous fiscal year. As a result, sales volume of RF Needle declined year on year, and sales decreased due to price competition.」
A competing product entered the market for RF Needle, formerly a unique product, resulting in lower sales volume and a decline in revenue due to price competition. - FY2023-Q3MaterialisedAnnual report
「In June 2022, we ended the exclusive distribution agreement for the drug-eluting coronary stent Orsiro ahead of schedule, and have continued to sell inventory at a limited number of facilities since the agreement ended. As a result, Orsiro revenue declined significantly year on year.」
Against a challenging competitive environment and delayed recovery in the number of procedures, sales were limited to inventory at selected facilities following the early termination of Orsiro's exclusive distribution agreement, and the impact of product-related risks continued through a significant decline in revenue. - FY2023-Q1MaterialisedAnnual report
「Although the high-frequency atrial septal puncture needle RF Needle had been sold as a unique product for many years since sales began in 2013, a competing product was launched in the previous fiscal year. As a result, sales volume of RF Needle declined year on year, and sales decreased due to price competition.」
A competing product was launched for the former unique product RF Needle, resulting in lower sales volume and a decline in revenue due to price competition. - FY2022MaterialisedAnnual report
「Although drug-eluting coronary stents were a core device in interventional procedures, sales remained below plan due to a challenging competitive environment and the decline in the number of procedures caused by COVID-19. The recognition of product valuation losses and other items put pressure on profits.」
Against intensified competition and a delayed recovery in the number of procedures, sales of Orsiro fell below plan, and the risk of product obsolescence and market change materialised in actual results through the recognition of product valuation losses and other items. - FY2022-Q3MaterialisedAnnual report
「Meanwhile, sales of drug-eluting coronary stents, which have also been affected by delays in the recovery in the number of procedures amid a challenging competitive environment, were below plan, resulting in the recognition of product valuation losses and other items.」
Against a challenging competitive environment and delayed recovery in the number of procedures, sales of drug-eluting coronary stents fell below plan, and the impact of product-related risks appeared in actual results through the recognition of product valuation losses and other items. - FY2021WorsenedAnnual report
「In particular, our 5 unique products currently account for approximately 40% of consolidated net sales for the fiscal year ending March 2021, and we recognise that the risk, if it materialises, would have a certain impact.」
Regarding the risk of product obsolescence, the company quantified the exposure by stating that its 5 unique products account for approximately 40% of consolidated net sales, specifying the potential scale of the risk's impact. - FY2021-Q2RestatedAnnual report
「No new business or other risks arose during the six-month period ended [the second quarter]. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company disclosed that there had been no material changes in the risk of declining market share due to product obsolescence or changes in treatment methods. - FY2020-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter of the current consolidated fiscal year. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company disclosed that there had been no material changes in the risk of declining market share due to product obsolescence or changes in treatment methods. - FY2020-Q2RestatedAnnual report
「No new business or other risks arose during the six-month period ended [the second quarter]. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company disclosed that there had been no material changes in the risk of declining market share due to product obsolescence or changes in treatment methods. - FY2020-Q1RestatedAnnual report
「No new business or other risks arose during the three-month period ended [the first quarter]. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company disclosed that there had been no material changes in the risk of declining market share due to product obsolescence or changes in treatment methods. - FY2019First statedAnnual report
「If competitors introduce medical devices similar to our unique products or treatment methods change significantly following the launch of innovative medical devices, our products' market share may decline, affecting the operating results and financial position of our group.」
The company identified the entry of products similar to its unique products and changes in treatment methods caused by innovative devices as new major risks of product obsolescence and declining market share. It also indicated that obtaining patents for its own products would reduce the risk of market entry.